LL-37 (LL37)

Immune Preclinical

Human cathelicidin antimicrobial peptide with broad-spectrum antimicrobial activity and immunomodulatory effects.

Key Data

Research Status
Preclinical
Half-Life
Unknown
Administration
Subcutaneous injection
Typical Dosage
100-200 mcg

Mechanism of Action

Direct antimicrobial action, immune cell activation, wound healing promotion.

Reported Benefits

All information is presented for Research Use Only (RUO). Not medical advice.

← All Peptides Dosing Calculator Community Forum Home